VaxGen Concludes Early Stage Meningitis B Vaccine Collaboration with EndoBiologics
VaxGen, Inc. announced that it is ending a collaboration with EndoBiologics International Corp. VaxGen announced in May 2005 that it would fund proof-of-concept studies and then determine whether to pursue commercial development of the vaccine candidate. The initial proof-of-concept phase was undertaken jointly by EndoBiologics and VaxGen, with VaxGen providing research funding to EndoBiologics and conducting pre-clinical testing of the vaccine candidate.
"Although we do not wish to pursue commercial development of this product, we will continue to look for other opportunities to develop a vaccine candidate against Meningitis B," said Lance K. Gordon, Ph.D., VaxGen's President and Chief Executive Officer.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.